SynthesisScientific reports2015
Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03137199 (A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma), which is not on this map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The efficacy and safety of omalizumab in the treatment of asthma: an overview of systematic reviews and meta analyses.Frontiers in medicine · 2025Pooled it
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2022Pooled it
- A meta-analysis of anti-interleukin-13 monoclonal antibodies for uncontrolled asthma.PloS one · 2019Pooled it
- Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.Therapeutic advances in respiratory diseasePooled it
- A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.Immunity, inflammation and disease · 2018Trial
- Managing Urticarial Vasculitis: A Clinical Decision-Making Algorithm Based on Expert Consensus.American journal of clinical dermatology · 2025Review
- Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.Dermatology and therapy · 2024Review
- Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.Dermatology and therapy · 2024Review
- Gene Therapy for Immunoglobulin E, Complement-Mediated, and Eosinophilic Disorders.Human gene therapy · 2023Review
- Transcriptomics reveals a distinct metabolic profile in T cells from severe allergic asthmatic patients.Frontiers in allergy · 2023Article
- Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.BMC pulmonary medicine · 2022Observational
- Pediatric usage of Omalizumab: A promising one.The World Allergy Organization journal · 2021Review
- Potential Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma.Advances in experimental medicine and biology · 2021Article
- Analysis of the immunoglobin E molecular sensitization profile in children with allergic asthma and predictive factors for the efficacy of allergy immunotherapy.Annals of translational medicine · 2020Article
- Past, present, and future of anti-IgE biologics.Allergy · 2020Review
- Beliefs and preferences regarding biological treatments for severe asthma.The World Allergy Organization journal · 2020Article
- Adherence to omalizumab: A multicenter "real-world" study.The World Allergy Organization journal · 2020Article
- Omalizumab induced Takotsubo syndrome: case report.European heart journal. Case reports · 2019Article
- Novel therapeutic targets for allergic airway disease in children.Drugs in context · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma, and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs; ≥52 weeks) was performed, and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations, and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.